Domain licenses Parkinson's drug candidates to Merck Serono spinoff

01/24/2013 | Genetic Engineering & Biotechnology News

Merck Serono spinoff Prexton Therapeutics was given an exclusive option by Domain Therapeutics to advance through clinical development stage its metabotropic glutamate receptor 4-positive allosteric modulator drug candidates against Parkinson's disease. The chemical series emerged from joint work by Domain and Merck Serono.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN